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drug trials; 2) to identify trials that speciﬁcally examined the
impact of treatment on patient-reported anxiety, depression and
sleep disturbance, as these common comorbid symptoms are
associated with poorer health status in people with epilepsy; and,
3) to identify which measures/domains were most responsive to
change. METHODS: A review of 41 adult epilepsy trials exam-
ining the impact of an oral antiepileptic drug on patient-reported
assessments of anxiety, depression, well-being, sleep, function
and treatment satisfaction. Studies were identiﬁed through
searches in MEDLINE, the Cochrane Central Register of Con-
trolled Trials and reference lists of published articles. RESULTS:
The most common types of PROs comprised epilepsy-speciﬁc
measures assessing multiple domains of functioning and well-
being (used in 30 studies) and generic measures assessing anxiety/
depression and other emotions (used in 21 studies). There was
limited detection of treatment effect on scales assessing anxiety/
depression and emotional well-being. Scales assessing per-
ceptions of emotional well-being were more likely to show
signiﬁcant differences than measures assessing symptom severity.
Patients were not required to have clinically signiﬁcant anxiety/
depression to participate. It is possible that patients entered trials
with symptoms in the normal range, leaving no room to show
improvement; that treatment did not worsen symptoms; or, that
instruments were not responsive. Findings were mixed regarding
other speciﬁc health status domains. Patients receiving active
treatments typically reported signiﬁcantly higher levels of satis-
faction than those receiving placebo. Only 2 trials were identiﬁed
that assessed patient-reported sleep, but both showed signiﬁcant
differences on speciﬁc domains. CONCLUSION: Anxiety and
depression were among the most common PROs assessed, but
there was limited detection of treatment effect. Trial selection
criteria complicate interpretation of ﬁndings. Patient-reported
sleep outcomes were rarely studied, but deserve more attention in
adult epilepsy drug trials.
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OBJECTIVES: To analyze longitudinal PRO measurements evo-
lution after treating refractory pain due to Trigeminal Neuralgia
in Primary Care Setting (PCS) during 12-weeks under routine
medical practice. METHODS: Sub-analysis of a sample of
patients above 18 years, with 6-month chronic pain due to
trigeminal neuralgia refractory to, at least, one previous analgesic
[previous mean (SD) number of drugs was 2.2 (1.2), with a
36.3% on one-drug only], included in a prospective, naturalistic,
12-weeks two-visit study on refractory peripheral Neuropathic
pain. PRO measurements included pain severity by McGill-pain
scale (included 50%-reduction responder rate and days with
no/mild pain), anxiety and depression symptoms (HAD scale),
sleep disturbances (MOS-sleep), disability (Sheehan scale), and
quality-adjusted-life-year (QALY) gain (EQ-5D). Paired non-
parametric and t-tests were applied. RESULTS: Ninety-one
[62.2% women, 57.7 (13.9) years] patients were analyzed: 45%
switched to pregabalin as a monotherapy, 37% received pregaba-
lin as add-on therapy, and in 18% previous treatment was
replaced by a regimen not including pregabalin. After 12 weeks
of therapy, signiﬁcant reduction in last-week mean pain severity
[-35.0 (23.9) mm, p < 0.0001, 53.9% responders] and percent-
age of subjects declaring the pain as severe or worst from 60.5%
to 10.5% (p < 0.0001), was accompanied by reductions in total
disability score [-8.2 (6.0) pts, p < 0.0001], depression symp-
toms score [-3.8 (4.2) pts, p < 0.0001], anxiety symptoms score
[-3.4 (3.3) pts, p < 0.0001], and summary-index sleep problems
scoring [-16.5 (18.4), p < 0.0001], while treatment increased the
quarterly mean number of days with no/mild pain [+32.3 (28.9)
days, p < 0.0001], the average number of sleeping-hours per
night [+0.8 (1.3), p < 0.0001], and produced a QALY gain of
0.0317 (0.0385). CONCLUSION: A therapy mix of painful
trigeminal neuralgia mostly based on pregabalin (82% of cases)
was associated with a signiﬁcant longitudinal improvement in
patient-reported-outcomes including severity of pain, symptoms
of depression and anxiety, disability, sleep disturbance and
quality-adjusted-life-year gain.
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OBJECTIVES: To review the Parkinson’s disease products
approved both in the United States (US) and in Europe with a
particular focus on the PRO end-points appearing in the prod-
ucts’ labels. METHODS: Parkinson’s disease products approved
in Europe since 1995 through the centralized procedure and in
the US since 1998 (new molecular entities) were identiﬁed from
a review of the EMEA and FDA websites. Using the PROLabels
database, we then identiﬁed the products indicated for Parkin-
son’s disease treatment and showing evidence of PRO in labeling.
PROLabels is a unique on-line tool which provides information
on the drug products for which the FDA and/or the EMEA have
granted PRO labeling claims. RESULTS: Overall, 10 different
products indicated for the treatment of Parkinson’s disease wAS
identiﬁed in this review, accounting for 7 different molecules. Of
these 10 drugs, 9 demonstrated the efﬁcacy of the treatment using
PRO endpoints. We will focus here on the 3 active molecules
approved both in Europe and in the US with a PRO labeling
claim. All six dossiers report the use of patient diaries to record
ON- and OFF-times. Other PRO endpoints assessed were health-
related quality of life (HRQL) and activities of daily living (ADL)
in two cases, and global functioning and levodopa dose in one
case. Regarding the methods of PRO measure, 4 products used a
deﬁned instrument to capture ADL and HRQL, and one used a
single item to assess functioning. CONCLUSION: Overall, PRO
data in labeling for Parkinson’s disease products is quite frequent
(in 9 out of 10 approved products), and above the average rate
over all therapeutic areas (source PROLabels). PRO endpoints
appeared mainly in the clinical studies section of the product
label. An interesting ﬁnding is the discrepancy between the
American and the European PRO claims.
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